Results 31 to 40 of about 313,394 (308)

Effect of drugs on bone mineral density in postmenopausal osteoporosis: a Bayesian network meta-analysis

Journal of Orthopaedic Surgery and Research, 2021
Background Osteoporosis affects mostly postmenopausal women, leading to deterioration of the microarchitectural bone structure and low bone mass, with an increased fracture risk with associated disability, morbidity and mortality.
Filippo Migliorini, N. Maffulli, Giorgia Colarossi, J. Eschweiler, M. Tingart, M. Betsch   +5 more
semanticscholar   +1 more source

Time to Benefit of Bisphosphonate Therapy for the Prevention of Fractures Among Postmenopausal Women With Osteoporosis: A Meta-analysis of Randomized Clinical Trials.

JAMA Internal Medicine, 2021
Importance The clinical decision to initiate bisphosphonate therapy for the treatment of osteoporosis requires balancing shorter-term harms and burdens (eg, gastroesophageal irritation or severe musculoskeletal pain) with longer-term benefits in reducing
W. Deardorff, I. Cenzer, Brian Nguyen, Sei J. Lee   +3 more
semanticscholar   +1 more source

LncRNA-NEF is downregulated in postmenopausal osteoporosis and is related to course of treatment and recurrence

Journal of International Medical Research, 2019
Objectives We investigated the role of long non-coding (lnc) RNA-NEF (neighboring enhancer of FoxA2), a characterized oncogene in cancer biology, in postmenopausal osteoporosis and its diagnostic and prognostic value in this disease.
Xiaoyong Ma, Zhixue Guo, Wenshan Gao, Jianzhong Wang, Yong Liu, Fei Gao, Shaosong Sun, Xiaozhe Zhou, Zhaoyu Yang, Wenkui Zheng   +9 more
doaj   +1 more source

Impact of postmenopausal osteoporosis on the lives of Omani women and the use of cultural and religious practises to relieve pain: A hermeneutic phenomenological study

Health Expectations, 2023
Introduction Osteoporosis is a significant clinical and public health concern worldwide. Despite the impact of this condition on women's lives, most studies have focused on its clinical manifestations, drug efficacy, and medical treatment.
Faiza Al Zadjali, Jane Brooks, Terence W. O'Neill, Emma Stanmore   +3 more
doaj   +1 more source

Biomarkers as therapy monitoring for postmenopausal osteoporosis: a systematic review

Journal of Orthopaedic Surgery and Research, 2021
Biochemical markers of bone turnover (BTMs), such as bone alkaline phosphatase (bALP), procollagen type I N propeptide (PINP), serum cross-linked C-telopeptides of type I collagen (bCTx), and urinary cross-linked N-telopeptides of type I collagen (NTx ...
Filippo Migliorini, N. Maffulli, F. Spiezia, M. Tingart, Peretti Giuseppe Maria, Giorgino Riccardo   +5 more
semanticscholar   +1 more source

Osteoporosis in postmenopausal women

Canadian Family Physician, 2021
How effective are bisphosphonates and denosumab for preventing fractures in postmenopausal women? Bisphosphonates and denosumab are similarly effective. Over 1 to 4 years, bisphosphonates or denosumab provide an absolute reduction of about 0.5% to 1.0% for hip fractures, 1.5% to 3 ...
Samantha, Moe, Allison, Paige, G Michael, Allan   +2 more
openaire   +2 more sources

Treatment of established osteoporosis: a systematic review and cost–utility analysis [PDF]

, 2002
Background and aims Osteoporosis is a systemic skeletal disease, characterised by low bone mass and microarchitectural deterioration of bone tissue with a subsequent increase in bone fragility and susceptibility to fracture.
J. E. Brazier, Stevenson, M., N.W. Calvert, J.A. Kanis, Kanis, JA, Stevenson, M, Calvert, N.W., Calvert, NW, M. Lloyd Jones, Brazier, JE, Lloyd Jones, M, Kanis, J.A., M. Stevenson, Brazier, J.E., Lloyd Jones, M., Calvert, N.   +15 more
core   +1 more source

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE.

Endocrine Practice, 2020
Objective: The development of these guidelines is sponsored by the American Association of Clinical Endocrinologists (AACE) Board of Directors and American College of Endocrinology (ACE) Board of Trustees and adheres with published AACE protocols for the
Pauline M. Camacho, S. Petak, Neil Binkley, Dima L. Diab, Leslie S. Eldeiry, A. Farooki, S. T. Harris, Daniel L. Hurley, Jennifer J Kelly, E. Lewiecki, Rachel Pessah-Pollack, M. McClung, Sunil J. Wimalawansa, Nelson B. Watts   +13 more
semanticscholar   +1 more source

Serum β-Catenin Levels Associated with the Ratio of RANKL/OPG in Patients with Postmenopausal Osteoporosis

International Journal of Endocrinology, 2013
Objective. To demonstrate the role of Wnt/β-catenin canonical pathway in postmenopausal osteoporosis by evaluating serum β-catenin levels in patients with postmenopausal osteoporosis and analyzing their possible relationship with serum OPG, RANKL, the ...
Xiao-Juan Xu, Lin Shen, Yan-Ping Yang, Rui Zhu, Bo Shuai, Cheng-Gang Li, Man-Xiang Wu   +6 more
doaj   +1 more source

Potential of biomarkers during pharmacological therapy setting for postmenopausal osteoporosis: a systematic review

Journal of Orthopaedic Surgery and Research, 2021
Background Biochemical markers of bone turnover (BTMs), such as the bone alkaline phosphatase (bALP), procollagen type I N propeptide (PINP), serum cross-linked C-telopeptides of type I collagen (bCTx), and urinary cross-linked N-telopeptides of type I ...
Filippo Migliorini, N. Maffulli, F. Spiezia, G. Peretti, M. Tingart, R. Giorgino   +5 more
semanticscholar   +1 more source